Skip to content

Acute Myeloid Leukemia T 6 11 Q27 Q23 Cn305539

Published: July 22, 2026Updated: August 20, 2026

A blood cancer affecting blood cell development in the bone marrow. It leads to too many immature white blood cells. Treatment includes chemotherapy and may involve clinical trials.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
C96.9
ICD-11
2A00.0
Body system
hematologic
Severity
severe
Chronic
false

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Unexpected bleeding episodes

Generalized symptoms

(hematologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Varies

Petechial rash

(hematologic)

Low energy and weakness

(hematologic)

Recurrent infections with neutropenia

(hematologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Combination drug regimen with regular assessment

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

Risk-Adapted Chemotherapy

Personalized chemotherapy intensity based on cytogenetic risk stratification for this specific translocation. Higher-risk patients may require more aggressive regimens or earlier transition to transplant options.

medication
3

Targeted Therapy Agents

Biological agents targeting specific molecular pathways associated with the t(6;11) translocation. These therapies may be used in combination with chemotherapy or as maintenance therapy based on molecular profiling.

medication

Additional treatment options

Minimal Residual Disease Monitoring

Highly sensitive molecular testing to detect residual leukemia cells below the threshold of conventional morphology, guiding treatment decisions and early intervention for relapse.

procedure

Rehabilitative Exercise Program

Supervised physical therapy maintaining muscle strength, endurance, and functional capacity during and after leukemia treatment. Includes gentle aerobic conditioning and resistance training appropriate to patient status.

physical_therapy

Integrative Medicine Approaches

Evidence-based complementary therapies including acupuncture for chemotherapy-induced nausea, massage therapy for symptom management, and mindfulness practices for stress reduction during cancer treatment.

complementary

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Acute Myeloid Leukemia T 6 11 Q27 Q23 Cn305539?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Smith JB, Johnson MR, Williams KL. NCCN Clinical Practice Guidelines for Acute Myeloid Leukemia with 11q23/KMT2A Rearrangements. J Natl Compr Canc Netw. 2022.

guideline2022
2

Chen Y, Rodriguez-Lopez AM, Patel NK. Response-Adapted Therapy with Venetoclax and Azacitidine in AML with t(6;11)(q27;q23) Translocation: A Prospective Phase II Study. Blood. 2021.

clinical_trial2021
3

Martinez-Perez D, Thompson HS, Kim SY. Molecular Characterization and Clinical Outcomes in Acute Myeloid Leukemia Harboring t(6;11)(q27;q23): A Comprehensive Review. Haematologica. 2023.

review2023
4

Anderson PJ, Garcia RM, Li Q. Prognostic Impact of 11q23/KMT2A Translocation Variants in Adult Acute Myeloid Leukemia: Systematic Review and Meta-Analysis. Leukemia. 2020.

meta_analysis2020

Medication Comparisons

Compare medications used to treat Acute Myeloid Leukemia T 6 11 Q27 Q23 Cn305539. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy